Oppenheimer Names Mindray in December's Top Ideas

A report from Oppenheimer reiterates its Outperform rating on Mindray

. The report states, “We view MR as a dominant key player in China's medical device industry. We think MR will grow on the back of US recovery, continuing high demand from emerging markets and pick-up of domestic demand. Our analysis of ShenZhen export data and Mindray's positive 1Q11 results convinced us that MR has successfully leveraged its Datascope investment. We believe MR's investment on sales and marketing and R&D will pay back and drive future revenue growth” MR closed Friday at $24.58.